Efficacy of a Chinese Herbal Medicine in Providing Adequate Relief of Constipation-predominant Irritable Bowel Syndrome: A Randomized Controlled Trial

Quigley, 2010, Practice guideline, irritable bowel syndrome: a global perspective, Arab J Gastroenterol, 11, 53, 10.1016/j.ajg.2009.12.016 Videlock, 2007, Irritable bowel syndrome: current approach to symptoms, evaluation and treatment, Gastroenterol Clin North Am, 36, 665, 10.1016/j.gtc.2007.07.002 Hungin, 2003, The prevalence, patterns and impact of IBS: an international survey of 40,000 subjects, Aliment Pharmacol Ther, 17, 643, 10.1046/j.1365-2036.2003.01456.x Irvine, 2006, Design of treatment trials for functional gastrointestinal disorders Badia, 2002, Burden of illness in irritable bowel syndrome comparing Rome I and Rome II criteria, Pharmacoeconomics, 20, 749, 10.2165/00019053-200220110-00004 Bensoussan, 2001, Application of the general health status questionnaire SF36 to patients with gastrontestinal dysfunction: inital validation and validation as a measure of change, Aust N Z J Public Health, 25, 71, 10.1111/j.1467-842X.2001.tb00554.x Hungin, 2003, The impact of IBS on absenteeism and work productivity: United States and eight European countries, Am J Gastroenterol, 98, S227, 10.1016/S0002-9270(03)01459-X Agarwal, 2011, The effect of irritable bowel syndrome on health-related quality of life and healthcare expenditures, Gastroenterol Clin North Am, 40, 11, 10.1016/j.gtc.2010.12.013 Tack, 2006, Systematic review: the efficacy of treatments for IBS—a European perspective, Aliment Pharmacol Ther, 24, 183, 10.1111/j.1365-2036.2006.02938.x Kellow, 2003, An Asia-Pacific, double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome, Gut, 52, 671, 10.1136/gut.52.5.671 Evans, 2004, Tegaserod for the treatment of irritable bowel syndrome, Cochrane Collab, 1 Drossman, 2009, Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome—results of two randomized, placebo-controlled studies, Aliment Pharmacol Ther, 3, 329, 10.1111/j.1365-2036.2008.03881.x Rao, 2012, A 12-week randomized controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation, Am J Gastroenterol, 107, 1714, 10.1038/ajg.2012.255 Russo, 1999, A national survey of practice patterns of gastroenterologists with comparison to the past two decades, J Clin Gastroenterol, 19, 339, 10.1097/00004836-199912000-00009 Sanders, 2005, The incidence of self-prescribed oral complementary and alternative medicine usage: do international variations exist?, J Clin Gastroenterol, 39, 836, 10.1097/01.mcg.0000177234.36640.68 Magge, 2011, Complementary and alternative medicine for the irritable bowel syndrome, Gastroenterol Clin North Am, 40, 245, 10.1016/j.gtc.2010.12.005 Lui, 2006, Herbal medicines for treatment of irritable bowel syndrome, Cochrane Database of Syst Rev, 1 Bensoussan, 1998, Treatment of irritable bowel syndrome with chinese herbal medicine: a randomized controlled trial, JAMA, 280, 1585, 10.1001/jama.280.18.1585 Brierley, 2011, Use of natural products in gastrointestinal therapies, Curr Opin Pharmacol, 11, 604, 10.1016/j.coph.2011.09.007 Zhu, 1991 2010 Camilleri, 2007, Primary endpoints for irritable bowel syndrome trials: a review of performance of endpoints, Clin Gastroenterol Hepatol, 5, 534, 10.1016/j.cgh.2007.03.004 Camilleri, 2015, Comparison of adequate relief with symptom, global, and responder endpoints in linaclotide phase 3 trials in IBS-C, United European Gastroenterol J, 3, 53, 10.1177/2050640614555946 Heaton, 1997, Stool form scale as a useful guide to intestinal transit time, Scand J Gastroenterol, 32, 920, 10.3109/00365529709011203 Patrick, 1997 Ware, 2007 Lovibond, 2004 Reilly, 2004, The validity and accuracy of the Work Productivity and Activity Impairment questionnaire: irritable bowel syndrome version (WPAI: IBS), Aliment Pharmacol Ther, 20, 459, 10.1111/j.1365-2036.2004.02091.x Hellström, 2011, Characteristics of acute pain attacks in patients with irritable bowel syndrome meeting Rome III criteria, Am J Gastroenterol, 106, 1299, 10.1038/ajg.2011.78 Amouretti, 2006, Impact of irritable bowel syndrome (IBS) on health-related quality of life (HRQOL), Gastroentérologie Clinique et Biologique, 30, 241, 10.1016/S0399-8320(06)73160-8